doi:10.3969/j.issn.1004-583X.2024.08.013

Abstract

CLC Number:

R587.1

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.08.013

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I8/758

Figures/Tables 1

References 43

[1]	Singh H, Singh R, Singh A, et al. Role of oxidative stress in diabetes-induced complications and their management with antioxidants[J]. Arch Physiol Biochem, 2023:1-26.
[2]	Mammadova-Bach E, Braun A. Zinc homeostasis in platelet-related diseases[J]. Int J Mol Sci, 2019, 20(21):5258.
[3]	Hongfang G, Guanghui C, Khan R, et al. Review: Molecular structure and functions of zinc binding metallothionein-1 protein in mammalian body system[J]. Pak J Pharm Sci, 2020, 33(4):1719-1726. pmid: 33583807
[4]	Barman S, Srinivasan K. Diabetes and zinc dyshomeostasis:Can zinc supplementation mitigate diabetic complications?[J]. Crit Rev Food Sci Nutr, 2022, 62(4):1046-1061.
[5]	Kirschke STCP. Zinc transporter7 deficiency affects lipid synthesis in adipocytes by inhibiting insulin-dependent Akt activation and glucose uptake[J]. FEBS J, 2016, 2(283):378-394.
[6]	Parsons DS, Hogstrand C, Maret W. The C-terminal cytosolic domain of the human zinc transporter ZnT8 and its diabetes risk variant[J]. FEBS J, 2018, 285(7):1237-1250. doi: 10.1111/febs.14402 pmid: 29430817
[7]	Catapano MC, Parsons DS, Kotuniak R, et al. Probing the structure and function of the cytosolic domain of the human zinc transporter ZnT8 with nickel(ii) ions[J]. Int J Mol Sci, 2021, 22(6):2940.
[8]	Xue J, Xie T, Zeng W, et al. Cryo-EM structures of human ZnT8 in both outward- and inward-facing conformations[J]. Elife, 2020, 9:e58823.
[9]	Daniels MJ, Jagielnicki M, Yeager M. Structure/function analysis of human ZnT8 (SLC30A8): A diabetes risk factor and zinc transporter[J]. Curr Res Struct Biol, 2020, 2:144-155.
[10]	Mashal S, Khanfar M, Al-Khalayfa S, et al. SLC30A8 gene polymorphism rs13266634 associated with increased risk for developing type 2 diabetes mellitus in Jordanian population[J]. Gene, 2021, 768:145279.
[11]	Dong F, Zhang BH, Zheng SL, et al. Association between SLC30A8 rs13266634 polymorphism and risk of T2DM and IGR in Chinese population: A systematic review and meta-analysis[J]. Front Endocrinol (Lausanne), 2018, 9:564.
[12]	Zeng Q, Tan B, Han F, et al. Association of solute carrier family 30 A8 zinc transporter gene variations with gestational diabetes mellitus risk in a Chinese population[J]. Front Endocrinol (Lausanne), 2023, 14:1159714.
[13]	Hu J. Toward unzipping the ZIP metal transporters: Structure, evolution, and implications on drug discovery against cancer[J]. FEBS J, 2021, 288(20): 5805-5825.
[14]	Liu Y, Batchuluun B, Ho L, et al. Characterization of zinc influx transporters (ZIPs) in pancreatic beta cells: Roles in regulating cytosolic zinc homeostasis and insulin secretion[J]. J Biol Chem, 2015, 290(30):18757-18769.
[15]	Ruz M, Andrews-Guzman M, Arredondo-Olguin M. Modulation of zinc transporter expressions by additional zinc in C2C12 cells cultured in a high glucose environment and in the presence of insulin or interleukin-6[J]. Biol Trace Elem Res, 2023, 201(7):3428-3437.
[16]	Shaghayegh Norouzi JASS. Zinc transporters and insulin resistance: Therapeutic implications for type 2 diabetes and metabolic disease[J]. J BIOMED, 2017, 24(1):87.
[17]	Adulcikas J, Sonda S, Norouzi S, et al. Targeting the zinc transporter ZIP7 in the treatment of insulin resistance and type 2 diabetes[J]. Nutrients, 2019, 11(2): 408.
[18]	Norouzi S, Adulcikas J, Henstridge DC, et al. The zinc transporter zip7 is downregulated in skeletal muscle of insulin-resistant cells and in mice fed a high-fat diet[J]. Cells, 2019, 8(7):663.
[19]	Fukunaka A, Fukada T, Bhin J, et al. Zinc transporter ZIP13 suppresses beige adipocyte biogenesis and energy expenditure by regulating C/EBP-beta expression[J]. PLoS Genet, 2017, 13(8):e1006950.
[20]	Hung YH, Kim Y, Mitchell SB, et al. Absence of Slc39a14/Zip14 in mouse pancreatic beta cells results in hyperinsulinemia[J]. Am J Physiol Endocrinol Metab, 2024, 326(1):E92-E105.
[21]	Zhang X, Guan T, Yang B, et al. Effects of ZnT8 on epithelial-to-mesenchymal transition and tubulointerstitial fibrosis in diabetic kidney disease[J]. Cell Death Dis, 2020, 11(7):544. doi: 10.1038/s41419-020-2731-6 pmid: 32681069
[22]	Chi Y, Zhang X, Liang D, et al. ZnT8 exerts anti-apoptosis of kidney tubular epithelial cell in diabetic kidney disease through TNFAIP3-NF-kappaB signal pathways[J]. Biol Trace Elem Res, 2023, 201(5):2442-2457.
[23]	Jiang Y, Xie X, Li Z, et al. Functional cooperation of RKTG with p53 in tumorigenesis and epithelial-mesenchymal transition[J]. Cancer Res, 2011, 71(8):2959-2968. doi: 10.1158/0008-5472.CAN-10-4077 pmid: 21385899
[24]	Wu K, Fei L, Wang X, et al. ZIP14 is involved in iron deposition and triggers ferroptosis in diabetic nephropathy[J]. Metallomics, 2022, 14(7):mfac034.
[25]	Tang Z, Wang P, Dong C, et al. Oxidative stress signaling mediated pathogenesis of diabetic cardiomyopathy[J]. Oxid Med Cell Longev, 2022, 2022:5913374.
[26]	Lin W, Li D, Cheng L, et al. Zinc transporter Slc39a8 is essential for cardiac ventricular compaction[J]. J Clin Invest, 2018, 128(2):826-833. doi: 10.1172/JCI96993 pmid: 29337306
[27]	Wang J. Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice[J]. J Cell Mol Med, 2019, 23(9):6319-6330. doi: 10.1111/jcmm.14520 pmid: 31270951
[28]	Luo Y, Zhao J, Han X, et al. Relationship between serum zinc level and microvascular complications in patients with type 2 diabetes[J]. Chin Med J (Engl), 2015, 128(24):3276-3282.
[29]	Huang S, Wang J, Men H, et al. Cardiac metallothionein overexpression rescues diabetic cardiomyopathy in Akt2-knockout mice[J]. J Cell Mol Med, 2021, 25(14):6828-6840. doi: 10.1111/jcmm.16687 pmid: 34053181
[30]	刘文娇, 马婧, 韩瑞钰, 等. 锌转运蛋白在糖尿病雄性大鼠性腺组织中的表达[J]. 中国男科学杂志, 2020, 34(5):7-12.
[31]	Sun B, Ma J, Te L, et al. Zinc-Deficient diet causes imbalance in zinc homeostasis and impaired autophagy and impairs semen quality in mice[J]. Biol Trace Elem Res, 2023, 201(5):2396-2406.
[32]	Zhang X, Guan T, Yang B, et al. A novel role for zinc transporter 8 in the facilitation of zinc accumulation and regulation of testosterone synthesis in leydig cells of human and mouse testicles[J]. METABOLISM, 2018, 88:40-50.
[33]	Hussein M, Fathy W, Hassan A, et al. Zinc deficiency correlates with severity of diabetic polyneuropathy[J]. Brain Behav, 2021, 11(10):e2349.
[34]	Ali M, Aziz T. The combination of zinc and melatonin enhanced neuroprotection and attenuated neuropathy in oxaliplatin-induced neurotoxicity[J]. Drug Des Devel Ther, 2022, 16:3447-3463.
[35]	Wang X, Wu W, Zheng W, et al. Zinc supplementation improves glycemic control for diabetes prevention and management: A systematic review and meta-analysis of randomized controlled trials[J]. Am J Clin Nutr, 2019, 110(1):76-90. doi: 10.1093/ajcn/nqz041 pmid: 31161192
[36]	Cai L, Tan Y, Watson S, et al. Diabetic cardiomyopathy-zinc preventive and therapeutic potentials by its anti-oxidative stress and sensitizing insulin signaling pathways[J]. Toxicol Appl Pharmacol, 2023, 477:116694.
[37]	Barman S, Pradeep SR, Srinivasan K. Zinc supplementation alleviates the progression of diabetic nephropathy by inhibiting the overexpression of oxidative-stress-mediated molecular markers in streptozotocin-induced experimental rats[J]. J Nutr Biochem, 2018, 54:113-129. doi: S0955-2863(16)30662-3 pmid: 29331868
[38]	Aziz NM, Kamel MY, Mohamed MS, et al. Antioxidant, anti-inflammatory, and anti-apoptotic effects of zinc supplementation in testes of rats with experimentally induced diabetes[J]. Appl Physiol Nutr Metab, 2018, 43(10):1010-1018. doi: 10.1139/apnm-2018-0070 pmid: 29726717
[39]	Hosseini R, Montazerifar F, Shahraki E, et al. The effects of zinc sulfate supplementation on serum copeptin, c-reactive protein and metabolic markers in zinc-deficient diabetic patients on hemodialysis: A randomized, double-blind, placebo-controlled trial[J]. Biol Trace Elem Res, 2022, 200(1):76-83.
[40]	Lu Y, Liu Y, Li H, et al. Effect and mechanisms of zinc supplementation in protecting against diabetic cardiomyopathy in a rat model of type 2 diabetes[J]. Bosn J Basic Med Sci, 2015, 15(1):14-20.
[41]	Ranasinghe P, Wathurapatha WS, Galappatthy P, et al. Zinc supplementation in prediabetes: A randomized double-blind placebo-controlled clinical trial[J]. J Diabetes, 2018, 10(5):386-397. doi: 10.1111/1753-0407.12621 pmid: 29072815
[42]	Liu F, Ma F, Kong G, et al. Zinc supplementation alleviates diabetic peripheral neuropathy by inhibiting oxidative stress and upregulating metallothionein in peripheral nerves of diabetic rats[J]. Biol Trace Elem Res, 2014, 158(2):211-218. doi: 10.1007/s12011-014-9923-9 pmid: 24615552
[43]	Olechnowicz J, Tinkov A, Skalny A, et al. Zinc status is associated with inflammation, oxidative stress, lipid, and glucose metabolism[J]. J Physiol Sci, 2018, 68(1):19-31. doi: 10.1007/s12576-017-0571-7 pmid: 28965330

参考文献	糖尿病模型	锌的剂量	效果
Barman等^[37]	链脲佐菌素链(Streptozocin, STZ)糖尿病大鼠	饮食中锌含量是正常的5倍和10倍,持续6周	通过补充对氧化的保护作用,应激诱发的炎症
Aziz等^[38]	2型糖尿病大鼠	10 mg/kg锌持续4周	降低空腹血糖, 胰岛素抵抗指数,高胆固醇血症
Lu等^[40]	2型糖尿病模型	15 mg/kg的 ZnSO4,持续8周	显著改善心肌病变,显著增加金属硫蛋白水平改善糖尿病小鼠睾丸氧化应激,凋亡等指标
Ranasinghe等^[41]	糖尿病前期受试者	每天20 mg硫酸锌,持续12个月	缓解糖尿病肾病的进展
Liu等^[42]	STZ糖尿病大鼠	5 mg/(kg·d), 持续4周	锌通过刺激金属硫蛋白合成和下调氧化应激,提高神经的传导率

参考文献	糖尿病模型	锌的剂量	效果
Barman等^[37]	链脲佐菌素链(Streptozocin, STZ)糖尿病大鼠	饮食中锌含量是正常的5倍和10倍,持续6周	通过补充对氧化的保护作用,应激诱发的炎症
Aziz等^[38]	2型糖尿病大鼠	10 mg/kg锌持续4周	降低空腹血糖, 胰岛素抵抗指数,高胆固醇血症
Lu等^[40]	2型糖尿病模型	15 mg/kg的 ZnSO4,持续8周	显著改善心肌病变,显著增加金属硫蛋白水平改善糖尿病小鼠睾丸氧化应激,凋亡等指标
Ranasinghe等^[41]	糖尿病前期受试者	每天20 mg硫酸锌,持续12个月	缓解糖尿病肾病的进展
Liu等^[42]	STZ糖尿病大鼠	5 mg/(kg·d), 持续4周	锌通过刺激金属硫蛋白合成和下调氧化应激,提高神经的传导率

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 43

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ma Jiannan, Tao Jie, Sang Dasen, Wu Shouling, Zhang Qi. Association of urinary transferrin with new-onset cardiovascular disease in type 2 diabetes mellitus [J]. Clinical Focus, 2024, 39(8): 700-705.
[2]	Xiong Lu, Guo Lian. Correlation of 25(OH)D and SUA/SCr with type 2 diabetes mellitus combined with non-alcoholic fatty liver disease [J]. Clinical Focus, 2024, 39(8): 706-711.
[3]	. [J]. Clinical Focus, 2024, 39(7): 650-653.
[4]	Yue Jianghong, Wang Heng, Cai Gang, Zhang Xuanming, Peng Xi. Efficacy and safety of sotagliflozin in the treatment of type 2 diabetes mellitus: A meta-analysis [J]. Clinical Focus, 2024, 39(7): 581-592.
[5]	Du Sina, Li Wei, Lin Yajing, Sun Jianguo, Mao Mao, Chen Jianwei, Sun Danbo, Mao Yushan. Application of insulin dose spectrum after an intensive insulin pump therapy in type 2 diabetes mellitus [J]. Clinical Focus, 2024, 39(7): 620-624.
[6]	Sun Hui, Liu Haiying, Ren Junhao, Li Jinxia. Bidirectional Mendelian randomization study of causality between body mass index and type 2 diabetes in a European population [J]. Clinical Focus, 2024, 39(4): 325-331.
[7]	. [J]. Clinical Focus, 2024, 39(3): 274-278.
[8]	Lv Shasha, Song Jinlan, Shi Jian. Mitochondrial mutation m.3243A> G associated with diabetes mellitus: One case report and literature review [J]. Clinical Focus, 2024, 39(2): 160-163.
[9]	Zhang Jianan, Sun Linlin, Zhan Xiaoyan, Li Bing. Correlation between serum Vitamin B₁₂ and mild cognitive impairment in elderly patients with type 2 diabetes mellitus [J]. Clinical Focus, 2024, 39(1): 34-37.
[10]	Liao Kunfeng, Yao Yisong, Yang Jinpan, Yang Xining, Li Yaru, Zhou Hongyan, Liang Piao. Status and influencing factors of fear of progression in patients with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(12): 1095-1100.
[11]	Shi Peihua, Lin Yanlin, Bi Lifang. Study on the correlation of NLR, PLR and MLR with type 2 diabetes mellitus complicated with coronary heart disease [J]. Clinical Focus, 2023, 38(11): 996-1001.
[12]	Yang Xin, Xu Huajiao. Bibliometric analysis of literatures reporting psychological intervention of patients with diabetes mellitus: Based on Web of Science [J]. Clinical Focus, 2023, 38(8): 731-736.
[13]	Jin Jiahui, Yang Yang, Qin Tong, He Yuxin, Su Meihua. Probiotic supplementation on improving glucose metabolism in patients with type 2 diabetes mellitus: A meta-analysis [J]. Clinical Focus, 2023, 38(7): 581-587.
[14]	Wu Yanan, Yan Tianmei, Liang Peng, Wei Limin. High-risk identification of depressive symptoms in middle-elderly patients with diabetes [J]. Clinical Focus, 2023, 38(6): 516-520.
[15]	Yang Minxing, Sun Lu, Ye Yun, Xu Wendong, Huang Xiaolin, Zhang Haiyun, Xu Yinglei. Characteristics of cognitive function and corresponding factors in young and middle-aged patients with type 2 diabetes with obstructive sleep apnea hypopnea syndrome [J]. Clinical Focus, 2023, 38(3): 216-220.